

## Review

# Transforming growth factor- $\beta$ and breast cancer Cell cycle arrest by transforming growth factor- $\beta$ and its disruption in cancer

Jeffrey Donovan and Joyce Slingerland

University of Toronto, and Toronto Sunnybrook Regional Cancer Centre and Sunnybrook and Women's College Health Sciences Centre, Toronto, Ontario, Canada

Received: 7 February 2000  
Accepted: 7 February 2000  
Published: 21 February 2000

*Breast Cancer Res* 2000, **2**:116–124

© Current Science Ltd

## Abstract

Altered responsiveness to extracellular signals and cell cycle dysregulation are hallmarks of cancer. The cell cycle is governed by cyclin-dependent kinases (cdks) that integrate mitogenic and growth inhibitory signals. Transforming growth factor (TGF)- $\beta$  mediates G<sub>1</sub> cell cycle arrest by inducing or activating cdk inhibitors, and by inhibiting factors required for cdk activation. Mechanisms that lead to cell cycle arrest by TGF- $\beta$  are reviewed. Loss of growth inhibition by TGF- $\beta$  occurs early in breast cell transformation, and may contribute to breast cancer progression. Dysregulation of cell cycle effectors at many different levels may contribute to loss of G<sub>1</sub> arrest by TGF- $\beta$ . Elucidation of these pathways in breast cancer may ultimately lead to novel and more effective treatments for this disease.

**Keywords:** breast cancer, cell cycle, cyclin-dependent kinase inhibitor, human mammary epithelial cells, transforming growth factor- $\beta$

## Introduction


TGF- $\beta$  is a potent inhibitor of mammary epithelial cell proliferation [1,2] and regulates mammary development *in vivo* [3–5]. Mammary-specific overexpression of TGF- $\beta$  in transgenic mice can induce mammary hypoplasia and inhibit tumourigenesis [6–8]. Although normal human mammary epithelial cells (HMECs) are exquisitely sensitive to TGF- $\beta$  [9], human breast cancer lines require 10-fold to 100-fold more TGF- $\beta$  to produce an antimitogenic response, and some show complete loss of this effect [10].

Although loss of growth inhibition by TGF- $\beta$  in human cancers can arise through loss of TGF- $\beta$  production or through mutational inactivation of the TGF- $\beta$  receptors and Smad signalling molecules [11,12], these defects are not

observed in most arrest-resistant cancer lines. This observation, and the frequent appearance of resistance to more than one inhibitory cytokine in human tumours [13] emphasize the importance of the cell cycle effectors of growth arrest induced by TGF- $\beta$  as targets for inactivation in cancer.

TGF- $\beta$  can either lengthen G<sub>1</sub> transit time or cause arrest in late G<sub>1</sub> phase [14]. This cell cycle arrest is usually reversible [15,16], but in some cases is associated with terminal differentiation [17,18,19]. Because TGF- $\beta$  arrests susceptible cells in the G<sub>1</sub> phase, a brief review of cell cycle regulation is presented. This is followed by a review of the multiple and often, complementary mechanisms that contributing to G<sub>1</sub> phase arrest by TGF- $\beta$  and of how they are disrupted in breast and other cancers.

**Figure 1**



The cell cycle. Cell cycle progression is governed by cyclin-dependent kinases (cdks), the activities of which are regulated by binding of cyclins, by phosphorylation and by the cdk inhibitors [the inhibitor of cdk4 (INK4) family: p15, p16, p18 and p19; and the kinase inhibitor protein (KIP) family: p21, p27 and p57].

**Cell cycle**

Cell cycle progression is governed by cdks, which are activated by cyclin binding [20,21] and inhibited by the cdk inhibitors [22,23]. The cdks integrate mitogenic and growth inhibitory signals and coordinate cell cycle transitions [24,25]. G<sub>1</sub> to S phase progression is regulated by D-type cyclin-, E-type cyclin- and cyclin A-associated cdks (Fig. 1). B-type cyclin-associated kinases govern G<sub>2</sub> and M phases. Both E-type and D-type cyclin-cdks contribute to phosphorylation of the retinoblastoma protein (pRb). Hypophosphorylated pRb binds members of the E2F and DP1 families of transcription factors, inhibiting these transcriptional activators and actively repressing certain genes. Phosphorylation of pRb in late G<sub>1</sub> phase liberates free E2F/DP1, allowing activation of genes required for S phase (for review [26]).

**Cyclin-dependent kinase regulation by phosphorylation**

Cdk activation requires phosphorylation of a critical threonine (Thr160 in cdk2 and Thr187 in cdk4). There are two mammalian kinases with *in vitro* cdk activating kinase (CAK) activity: cyclin H/cdk7 and the protein encoded by the human homolog of the *Saccharomyces cerevisiae* CAK1, called Cak1p (for review [27]). The specific roles of these two kinases are somewhat controversial. CAK is active throughout the cell cycle [20,28], but its access to cyclin-bound cdks is inhibited by p27 [29]. Cdks are also negatively regulated by phosphorylation of specific inhibitory sites [27]. Cdc25 phosphatase family members must dephosphorylate these inhibitory sites for full cdk activation. Cdc25A acts on cyclin E-bound cdk2 and is required for G<sub>1</sub> to S phase progression [30].

**Cyclin-dependent kinase inhibitors**

Two cdk inhibitor families regulate the cell cycle [22,23]. The inhibitor of cdk4 (INK4) family members (p15<sup>INK4B</sup>, p16<sup>INK4A</sup>, p18<sup>INK4C</sup> and p19<sup>INK4D</sup>) inhibit specifically cdk4 and cdk6. The p16 gene, or MTS1 (Multi-Tumor Suppressor 1), was discovered as a tumour suppressor that is deleted in many cancers [31]. Loss of p15, located near p16 on chromosome 9p, may contribute to loss of G<sub>1</sub> arrest by TGF-β (see below).

The kinase inhibitor protein (KIP) family presently consists of three members, p21<sup>WAF1/Cip1</sup>, p27<sup>Kip1</sup> and p57<sup>Kip2</sup>. The KIPs bind and inhibit a broader spectrum of cdks than do the INK4s. p21 is low in serum-deprived quiescence, but p21 levels and p21 binding to D-type cyclin-cdk complexes increase in early G<sub>1</sub> phase. In addition to regulating G<sub>1</sub> phase progression, p21 acts to coordinate cell cycle responses to DNA damage [23]. p27<sup>Kip1</sup> was first identified as a heat stable protein whose binding to cyclin E-cdk2 complexes that was increased by TGF-β, lovastatin, or contact inhibition [32\*,33,34\*,35\*,36]. p27 is high in G<sub>0</sub> and early G<sub>1</sub> phase and decreases during G<sub>1</sub> to S phase progression. p27 degradation by ubiquitin-dependent proteolysis [37] is activated by many different growth factors and may involve ras pathways [38–42]. Although cyclin E-cdk2 phosphorylates p27 on Thr187 leading to its degradation in late G<sub>1</sub> phase [43,44], other kinases may also influence p27 function and/or degradation. The possibility that mitogenic signalling pathways that modulate p27 phosphorylation also oppose Smad activation by TGF-β is the subject of intensive investigation.

Although p21 and p27 inhibit cyclin E-cdk2, they also function in the assembly and activation of cyclin D-cdk4 and cyclin D-cdk6 complexes. KIP-mediated assembly of D-type cyclin-cdks in early G<sub>1</sub> phase may facilitate activation of E-type cyclin-cdks through sequestration of KIPs away from cyclin E complexes [45\*,46\*].

**Mechanisms of cell cycle arrest by TGF-β**

**TGF-β inhibits phosphorylation of the retinoblastoma protein**

Cells are sensitive to TGF-β during a discrete period in early G<sub>1</sub> phase, until they reach a ‘restriction point’ 6–10 h after G<sub>0</sub> release [47\*,48]. When TGF-β is added after this critical time point, cells complete the cell cycle but arrest during the subsequent G<sub>1</sub> phase. Laiho *et al* [47\*] observed that TGF-β inhibits pRb phosphorylation when it is added in early G<sub>1</sub> phase. This key observation suggested that TGF-β was acting before the G<sub>1</sub> to S phase transition to inhibit a pRb kinase, and led to the investigation of TGF-β effects on cell cycle regulators. These studies have shown that TGF-β prevents or inhibits G<sub>1</sub> cyclin-cdk activation through multiple mechanisms, leading to pRb dephosphorylation (Fig. 2). E2F activity is also impaired by TGF-β through a decline in E2F mRNA levels [49]. The observation that E2F overexpression can

prevent TGF-β-mediated arrest [49] emphasizes the importance of the effects of TGF-β on pRb and E2F.

**TGF-β downregulates c-myc**

In many cell types, TGF-β causes a rapid inhibition of *c-myc* transcription [2,16,50]. Transcriptional regulation by the c-Myc protein is required for G<sub>1</sub> to S phase progression. Downregulation of *c-myc* by TGF-β is believed to be important for arrest, because *c-myc* overexpression causes TGF-β resistance [2,51\*]. Repression of the *c-myc* gene by TGF-β may directly or indirectly contribute to the loss of G<sub>1</sub> cyclins [52,53], to downregulation of Cdc25A [54\*] and to the induction of the cdk inhibitor p15 [55\*] (see below).

**Effects on G<sub>1</sub>/S cyclins**

TGF-β causes loss of G<sub>1</sub> cyclins in a cell-type-dependent manner. Cyclin A expression is downregulated by TGF-β in most cell types [32\*,56\*] and a TGF-β-regulated region of the cyclin A promoter has been identified [57]. Effects of TGF-β on cyclin E differ among different cell lines. For example, in HaCat keratinocytes TGF-β decreases both mRNA and protein levels of cyclin A and cyclin E, whereas in HMECs cyclin E mRNA is reduced but protein levels are not [32\*,56\*]. Although cyclin D<sub>1</sub> levels are decreased by TGF-β in some cell types, this usually occurs late as a consequence of arrest [58,59\*].


**Cooperation between p15 and p27**

In epithelial cells, including HMECs, the INK4 and the KIP proteins collaborate to inhibit D-type cyclin-cdks and E-type cyclin-cdks to bring about G<sub>1</sub> arrest by TGF-β [60\*,61\*]. *p15<sup>INK4B</sup>* was first cloned as a gene upregulated by TGF-β [62\*] and its induction involves an Sp1 site in the promoter [63]. TGF-β induces *p15<sup>INK4B</sup>* and stabilizes the p15 protein, leading to p15 binding and inhibition of cdk4 and cdk6. Cyclin D<sub>1</sub> and KIP molecules dissociate from cdk4 and cdk6, and p27 accumulates in cyclin E-cdk2 complexes, inhibiting the latter [60\*,61\*]. A late downregulation of cyclin D<sub>1</sub> and cdk4 follows G<sub>1</sub> arrest. TGF-β appears to actively regulate p27's affinity for its targets, independent of p15 function, favouring p27 accumulation in cyclin E complexes [61\*].

**Upregulation of p21 expression**

In normal HMECs, TGF-β affects neither p21 levels, nor the binding of p21 to target cdks [61\*]. In other cell types, TGF-β induction of *p21* plays a role in cdk inhibition [59\*,64\*,65] and its upregulation is independent of p53 [64\*,66\*]. The *p21* gene may be a downstream target of Smad4, because transient overexpression of *Smad4* induces *p21* mRNA [67]. Like *p15*, the *p21<sup>WAF1/Cip1</sup>* gene promoter contains Sp1 sites that are regulated by TGF-β in reporter gene assays [63,68]. Other cdk inhibitors, p16, p18, p19 and p57, have not to date been implicated in TGF-β-mediated arrest.

**Figure 2**



Mechanisms of cell cycle arrest by transforming growth factor (TGF)-β and their deregulation in cancer. TGF-β receptor activation leads to Smad2 phosphorylation. Phosphorylated Smad2 then binds Smad4 and the Smad2-Smad4 complex translocates to the nucleus to modulate transcription. Although *p15* and *p21* genes are induced and *c-myc* and *Cdc25A* repressed by TGF-β, these may not be direct effects of Smad2-Smad4 action (dotted lines). TGF-β inhibits G<sub>1</sub> cyclin-cyclin-dependent kinases (cdks) by increasing p15 binding to cdk4 and cdk6 and by increasing p27 (+/- p21) binding to cyclin E-cdk2, thereby inhibiting retinoblastoma protein (pRb) phosphorylation. \*Components of the TGF-β effector pathway that are mutated and/or functionally inactivated in human cancers; \*\*molecules whose activation or overexpression may contribute to TGF-β arrest resistance.

**Effects on cdk2 phosphorylation**

TGF-β also regulates cdk2 phosphorylation. In Mv1Lu cells, TGF-β inhibits cdk2 in part by inhibiting phosphorylation on Thr160 [32\*,34\*]. p27 can inhibit CAK access to cyclin-bound cdks *in vitro* [29]. Thus, TGF-β may prevent CAK action by increasing the binding of p27 to cyclin E-cdk2. In HepG2 cells, however, TGF-β inhibits the enzymatic activity of Cak1p [69], indicating an alternative mechanism for the inhibition by TGF-β of Thr160 phosphorylation of cdk2.

Dephosphorylation of inhibitory sites on cyclin E-bound cdk2 is required for G<sub>1</sub> progression and is required for G<sub>1</sub> to S phase progression [30]. In a human breast epithelial line, TGF- $\beta$  reduced *Cdc25A* expression in association with an increase in inhibitory cdk phosphorylation [54\*]. The effect on *Cdc25A* expression may be secondary to the repression by TGF- $\beta$  of *c-myc*, because in some cell types *Cdc25A* is induced by *c-myc* [70\*].

### Loss of TGF- $\beta$ mediated G<sub>1</sub> arrest in cancer

In nontransformed epithelial cells, TGF- $\beta$  causes G<sub>1</sub> arrest through downregulation of *c-myc*, inhibition of the G<sub>1</sub> cdk and hypophosphorylation of pRb. Overlapping or redundant cell cycle controls assure growth arrest. In malignant transformed cells, however, this redundancy is often lost and carcinoma-derived cells are usually refractory to growth inhibition by TGF- $\beta$  [10]. Indeed, in advanced cancers, TGF- $\beta$  may promote tumour growth and metastatic progression [71]. In this part of the discussion, we review how dysregulation of many different cell cycle mechanisms abrogate TGF- $\beta$  arrest in cancer (Fig. 2).

### Altered cdk inhibitor expression and function

Dysregulation of the INK4 family may contribute to TGF- $\beta$  resistance in cancer. In human tumours, deletion of *p15* often accompanies *p16* deletion due to their proximity on chromosome 9p [72–74]. Silencing of *p15* through promoter hypermethylation, which is observed in leukaemias, is associated with loss of TGF- $\beta$  sensitivity [75,76]. In other TGF- $\beta$ -resistant cells, however, *p15* protein levels may increase normally, indicating that, at least in these lines, a functional *p15* is not sufficient to mediate arrest by TGF- $\beta$  [65].

Although *p15* and *p27* cooperate to inhibit the G<sub>1</sub> cyclin-cdks in normal cells, neither of these cdk inhibitors are essential for G<sub>1</sub> arrest by TGF- $\beta$ . *p15* is clearly not essential for TGF- $\beta$ -mediated G<sub>1</sub> arrest, because cells bearing *p15* deletions can respond through upregulation of *p21* and *p27* [59\*,65], or downregulation of *Cdc25A* [54\*]. Lymphocytes from *p27*-null mice can still arrest in response to TGF- $\beta$  [77]. Nonetheless, the requirement for *p27* in arrest by TGF- $\beta$  may differ in normal and transformed cells. Although inhibition of *p27* expression through antisense *p27* oligonucleotide transfection did not abrogate TGF- $\beta$ -mediated arrest in finite lifespan HMECs, it did do so in breast cancer-derived lines (Donovan J, Slingerland J, unpublished data). In normal cells, multiple redundant pathways cooperate to mediate arrest, but in cancer cells the progressive loss of other checkpoints may make *p27* indispensable for TGF- $\beta$ -mediated arrest.

The antiproliferative role of *p27* is frequently disrupted in human cancers. Although mutations in *p27* are rare [78,79], accelerated proteolysis causes reduced *p27*

protein in many cancers, including breast, and may contribute to TGF- $\beta$  resistance [37,80–82]. Less often, primary tumours may exhibit strong cytoplasmic *p27* expression associated with poor prognosis. Cytoplasmic *p27* has been observed in some advanced cancer-derived lines [83]. Thus, some cancers may express a stable but inactivated *p27*. In a TGF- $\beta$ -resistant HMEC line, we have observed stable cytoplasmic *p27* localization, altered *p27* phosphorylation and impaired binding of *p27* to cyclin E-cdk2 (Ciarallo S, Slingerland J, unpublished data). The elucidation of how of mitogenic signalling pathways alter *p27* inhibitor function may prove important insights into mechanisms of TGF- $\beta$  resistance (see below).

Altered KIP function has also been observed in TGF- $\beta$ -resistant prostate cancer cells. Although TGF- $\beta$  caused an upregulation in *p21*-cdk2 binding, this kinase was not inhibited, suggesting that *p21* may not function normally in these cells [84]. Loss of *p21* has also been observed in advanced breast cancers in association with a poor patient prognosis [85,86]. As for *p27*, functional inactivation of *p21* could contribute to TGF- $\beta$  resistance during breast cancer progression.

### Cyclin overexpression and TGF- $\beta$ resistance

Overexpression and/or amplification of the cyclin D<sub>1</sub> gene is seen in up to 40% of breast cancers [87,88] and could contribute to TGF- $\beta$  resistance. Indeed, cyclin D<sub>1</sub> transfection of an oesophageal epithelial line conferred resistance to TGF- $\beta$  [89]. Increased cyclin E protein has also been observed in breast cancers [80,90]. Constitutive overexpression of cyclin E does not confer TGF- $\beta$  resistance in Mv1Lu cells, however (Slingerland J, Reed S, unpublished data). Pathways that link impaired cyclin degradation with loss of cell cycle responses to TGF- $\beta$  have yet to be elucidated.

### Cdk4 gene amplification and activating mutation

Although loss of *cdk4* does not contribute significantly to arrest by TGF- $\beta$  because it occurs after most cells have entered G<sub>1</sub> phase [60\*], ectopic *cdk4* expression can abrogate TGF- $\beta$ -mediated arrest [91\*]. The increased *cdk4* level may exceed titration by *p15* and, in addition, sequestration of KIPs away from cyclin E-cdk2 into newly formed cyclin D-cdk4 complexes may lead to loss of *cdk2* inhibition. Overexpression of *cdk4* may contribute to TGF- $\beta$  resistance in human cancers. Amplification of the *cdk4* gene occurs in primary breast cancers [92] and dominant active *cdk4* mutations have been observed in human malignant melanoma [31].

### Activation of *c-myc*, and TGF- $\beta$ resistance

TGF- $\beta$  arrest-resistant cells often fail to downregulate *c-myc* [65]. Moreover, oncogenic activation of *c-myc*, which is seen in a number of human malignancies, including breast cancer, may impair TGF- $\beta$  responsiveness through a number of mechanisms.

Overexpression of c-Myc may increase G<sub>1</sub> cyclin levels. c-Myc may regulate indirectly the expression of cyclins D<sub>1</sub>, E and A [52,53]. c-Myc induction of cyclin D<sub>1</sub> or cyclin D<sub>2</sub> may lead to the sequestration of p27 and p21 away from cyclin E-cdk2, and thus contribute to cyclin E-cdk2 activation [93,94]. These effects, however, which are best demonstrated in fibroblast lines, may not be relevant to TGF-β resistance in epithelial cells. In Mv1Lu cells, c-myc overexpression prevents arrest by TGF-β in part by inhibiting p15 induction [55\*]. c-Myc effects on D-type cyclin expression and cyclin D-cdk4 complex formation were not sufficient to account for loss of the TGF-β response. Thus, repression of p15 by c-Myc may be important in the arrest-resistant phenotype.

Additional mechanisms link c-Myc with cyclin E-cdk2 activation. Overexpression of c-myc can induce a heat labile factor that binds p27 and inhibits its association with cyclin E-cdk2 [95]. This effect is independent of p27 degradation. Although in some cell types cyclins D<sub>1</sub> and D<sub>2</sub> may be the c-myc-induced inhibitors of p27 [93,94], in other models the c-myc-induced inhibitor of p27 appears to be independent of D-type cyclins [95].

Oncogenic activation of c-myc may lead to *Cdc25A* overexpression and loss of TGF-β-mediated repression of *Cdc25A* [54\*]. Overexpression of *Cdc25A* is observed in primary breast cancers and is associated with a poor patient prognosis (Loda M, personal communication). The increased *Cdc25A* may represent one of the checkpoints whose disruption makes subsequent disruption of p27 function more critical during breast cancer progression.

#### Activation of Ras and its effector pathways and TGF-β resistance

Overexpression of activated Ras has been shown to abrogate the antimitogenic effects of TGF-β [96]. Mutational activation of *ras* is common in many human cancers and may be linked to TGF-β resistance through a number of mechanisms. Activated Ras can interfere with TGF-β signalling by altering Smad2 phosphorylation and signal transduction [97]. Moreover, Ras activation can increase cyclin D<sub>1</sub> levels through both transcriptional and post-translational mechanisms [38,98,99]. Ras activation also accelerates p27 degradation [40,41], in some models requiring coexpression of Myc [39]. Although *ras* mutations are not commonly observed in breast cancer, epidermal growth factor (EGF) and ErbB2 overexpression are, and both activate the Ras effector phosphatidylinositol-3 kinase [100]. Oncogenic activation of different *ras* effector pathways may abrogate p27 function [41,101], contributing importantly to TGF-β resistance.

#### Regulation of other G<sub>1</sub> events by TGF-β

p53 may play a role in the TGF-β response in some cells. In murine keratinocytes, introduction of mutated p53 led to

TGF-β resistance, and a correlation between p53 mutation and loss of responsiveness to TGF-β-mediated arrest has been observed in several cancers [102–104].

Constitutive expression of *mdm2* can give rise to TGF-β resistance. Although the Mdm2 protein binds to p53 to mediate p53 proteolysis, the effects of Mdm2 on TGF-β sensitivity appear to be independent of p53 function, because expression of an Mdm2 mutant that failed to bind p53 also conferred resistance [105]. Because overexpression of Mdm2 occurs in about 73% of breast cancers, this too may play a role in TGF-β resistance *in vivo* [85,106,107].

#### Conclusion

During the past decade the anatomy of cell cycle regulation has been 'worked out'. TGF-β-induced G<sub>1</sub> arrest occurs through induction of p15 and p21 genes, repression of the c-myc, *Cdc25A*, *cyclin E* and *cyclin A* genes, and an increase in the association of p15, p21 and p27 with target cdks. Inactivation of G<sub>1</sub> cyclin-cdks leads to pRb dephosphorylation and E2F inhibition. The discovery of the Smads as both transducers of TGF-β signalling and transcriptional regulators has been a major advance in this field. Mitogenic signalling via ras/mitogen-activated protein kinase has been shown to interfere with Smad activation [11]. It will be of interest to ascertain whether cross-talk with Smads can also negatively regulate components of mitogenic signal transduction pathways. How growth factors and mitogenic pathways influence the transcriptional activation, intracellular localization and degradation of cyclins and cdk inhibitors is only beginning to be mapped. As these mechanisms are elucidated, we will be able to move from the myopic view of cyclin-cdk regulation in the nucleus, to a broader three-dimensional view of cell cycle regulation that encompasses extracellular and cytoplasmic signalling pathways. The next frontiers lie in the cytoplasm and at the gateway of the nuclear pore as we begin to elucidate how TGF-β/Smad signalling interfaces with transducers of mitogenic signals to regulate cyclin-cdk activities.

#### Acknowledgements

We thank members of the Slingerland laboratory for critical reading of the manuscript and Ms Sophie Ku for excellent secretarial assistance.

#### References

Articles of particular interest have been highlighted as:

- of special interest
- of outstanding interest

1. Massague J, Cheifetz S, Laiho M, et al: **Transforming growth factor-β**. *Cancer Surv* 1992, 12:81–103.
2. Alexandrow MG, Moses H: **Transforming growth factor β and cell cycle regulation**. *Cancer Res* 1995, 55:1452–1457.
3. Daniel CW, Silberstein GB, van Horn K, Strickland P, Robinson S: **TGF-β1-induced inhibition of mouse mammary ductal growth: developmental specificity and characterization**. *Dev Biol* 1989, 135:20–30.

4. Silberstein GB, Daniel CW: **Reversible inhibition of mammary gland growth by transforming growth factor- $\beta$** . *Science* 1987, **237**: 291–293.
5. Barcellos-Hoff MH, Ewan KB: **Transforming growth factor- $\beta$  and breast cancer: mammary gland development** *Breast Cancer Res* 2000, **2**:92–99
6. Pierce DFJ, Johnson MD, Matzui Y, et al: **Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF- $\beta$ 1**. *Genes Dev* 1993, **7**:2308–2317.
7. Pierce DF, Gorska AE, Chytil A, et al: **Mammary tumor suppression by transforming growth factor  $\beta$ 1 transgene expression**. *Proc Natl Acad Sci USA* 1995, **92**:4254–4258.
8. Wakefield LM: **Transforming growth factor- $\beta$  and breast cancer: lessons learned from genetically altered mouse models**. *Breast Cancer Res* 2000, **2**:100–106.
9. Hosobuchi M, Stampfer M: **Effects of the transforming growth factor  $\beta$  on growth of human mammary epithelial cells in culture**. *In Vitro Cell Dev Biol* 1989, **25**:705–713.  
A demonstration is provided that normal, finite lifespan HMECs all undergo arrest in response to TGF- $\beta$ .
10. Fynan TM, Reiss M: **Resistance to inhibition of cell growth by transforming growth factor-beta and its role in oncogenesis**. *Crit Rev Oncogenesis* 1993, **4**:493–540.
11. Massague J: **TGF- $\beta$  signal transduction**. *Annu Rev Biochem* 1998, **67**:753–791.
12. Kretzschmar M: **Transforming growth factor- $\beta$  and breast cancer: transforming growth factor- $\beta$ /SMAD signaling defects and cancer**. *Breast Cancer Res* 2000, **2**:107–115.
13. Kerbel RS: **Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer: malignant melanoma as a paradigm**. *Am J Pathol* 1992, **141**:519–524.
14. Massague J: **The transforming growth factor- $\beta$  family**. *Ann Rev Cell Biol* 1990, **6**:597–641.
15. Shipley GD, Pittelkow MR, Wille JJ, Scott RE, Moses HL: **Reversible inhibition of normal human prokeratinocyte proliferation by type  $\beta$  transforming growth factor-growth inhibitor in serum-free medium**. *Cancer Res* 1986, **46**:2068–2071.  
This study showed that G<sub>1</sub> arrest by TGF- $\beta$  in normal human prokeratinocytes was reversible.
16. Coffey RJ, Bascom CC, Sipes NJ, et al: **Selective inhibition of growth-related gene expression in murine keratinocytes by transforming growth factor beta**. *Mol Cell Biol* 1988, **8**:3088–3093.
17. Zentella A, Massague J: **Transforming growth factor beta induces myoblast differentiation in the presence of mitogens**. *Proc Natl Acad Sci USA* 1992, **89**:5176–5180.  
This paper showed that TGF- $\beta$  mediated irreversible cell cycle arrest and differentiation of myoblasts.
18. Masui T, Wakefield LM, Lechner JF, et al: **Type  $\beta$  transforming growth factor is the primary differentiation inducing serum factor for normal human bronchial epithelial cells**. *Proc Natl Acad Sci USA* 1986, **83**:2438–2442.
19. Jetten AM, Shirley JE, Stoner G: **Regulation of proliferation and differentiation of respiratory tract epithelial cells by TGF- $\beta$** . *Exp Cell Res* 1986, **167**:539–549.
20. Morgan DO: **Principles of Cdk regulation**. *Nature* 1995, **374**: 131–134.
21. Sherr CJ: **G1 phase progression: cycling on cue**. *Cell* 1994, **79**: 551–555.
22. Sherr CJ, Roberts JM: **Inhibitors of mammalian G1 cyclin-dependent kinases**. *Genes Dev* 1995, **9**:1149–1163.
23. Sherr CJ, Roberts JM: **CDK inhibitors: positive and negative regulators of G1-phase progression**. *Genes Dev* 1999, **13**:1501–1512.
24. Murray AW: **Creative blocks: cell cycle checkpoints and feedback controls**. *Nature* 1992, **359**:599–604.
25. Hartwell L: **Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells**. *Cell* 1992, **71**:543–546.
26. Adams PD, Kaelin WG: **Transcriptional control by E2F**. *Semin Cancer Biol* 1995, **6**:99–108.
27. Solomon MJ, Kaldis P: **Regulation of CDKs by phosphorylation**. *Results Probl Cell Diff* 1998, **22**:79–109.
28. Solomon MJ: **Activation of the various cyclin/cdc2 proteins**. *Curr Opin Cell Biol* 1993, **5**:180–186.
29. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ: **Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation**. *Cell* 1994, **79**:487–496.
30. Draetta G, Eckstein J: **Cdc25 protein phosphatases in cell proliferation**. *Biochim Biophys Acta* 1997, **1332**:M53–M63.
31. Bates S, Peters G: **Cyclin D1 as a cellular proto-oncogene**. *Semin Cancer Biol* 1995, **6**:73–82.
32. Slingerland JM, Hengst L, Pan C-H, et al: **A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor  $\beta$ -arrested epithelial cells**. *Mol Cell Biol* 1994, **14**:3683–3694.  
TGF- $\beta$  caused inhibition of cyclin E-cdk2 and cyclin A-cdk2 through the induction of a heat stable inhibitor that bound to target cdk. This protein was later shown to be p27. TGF- $\beta$  was also shown to inhibit CAK activation of cdk2 in the Mv1Lu cell line.
33. Hengst L, Dulic V, Slingerland J, Lees E, Reed SI: **A cell cycle regulated inhibitor of cyclin dependant kinases**. *Proc Natl Acad Sci USA* 1994, **91**:5291–5294.
34. Koff A, Ohtsuki M, Polyak K, Roberts JM, Massague J: **Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF- $\beta$** . *Science* 1993, **260**:536–539.  
TGF- $\beta$  inhibits G<sub>1</sub> progression through inhibition of cyclin E-dependent and cyclin A-dependent kinases and through inhibition of the activating phosphorylation of cdk2.
35. Polyak K, Kato JY, Solomon MJ, et al: **p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor- $\beta$  and contact inhibition to cell cycle arrest**. *Genes Dev* 1994, **8**:9–22.  
It was demonstrated that TGF- $\beta$ -mediated arrest involved the action of a 27-kDa protein, p27<sup>Kip1</sup>, that bound and inhibited cyclin E-cdk2.
36. Polyak C, Lee M-H, Erdjument-Romage H, et al: **Cloning of p27KIP1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals**. *Cell* 1994, **78**:59–66.
37. Slingerland J, Pagano M: **Regulation of the Cdk inhibitor p27 and its deregulation in cancer**. *J Cell Physiol* 2000, **183**:10–17.
38. Aktas H, Cai H, Cooper GM: **Ras links growth factor signalling to the cell cycle machinery via regulation of cyclin D1 and the cdk inhibitor p27<sup>Kip1</sup>**. *Mol Cell Biol* 1997, **17**:3850–3857.
39. Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR: **Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F** [published erratum appears in *Nature* 1997, **387**:932]. *Nature* 1997, **387**:422–426.
40. Kawada M, Yamagoe S, Murakami Y, et al: **Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway**. *Oncogene* 1997, **15**:629–637.

41. Takuwa N, Takuwa Y: **Ras activity late in G1 phase required for p27kip1 downregulation, passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 3T3 fibroblasts.** *Mol Cell Biol* 1997, **17**:5348–5358.
42. Hu W, Bellone CJ, Baldassare JJ: **RhoA stimulates p27 Kip degradation through its regulation of cyclin E/Cdk2 activity.** *J Biol Chem* 1999, **274**:3396–3401.
43. Vlach J, Hennecke S, Amati B: **Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27<sup>Kip1</sup>.** *EMBO J* 1997, **16**:5334–5344.
44. Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE: **Cyclin E-CDK2 is a regulator of p27Kip1.** *Genes Dev* 1997, **11**:1464–1478.
45. LaBaer J, Garret M, Steenson M, *et al*: **New functional activities for the p21 family of cdk inhibitors.** *Genes Dev* 1997, **11**:847–862.  
This study demonstrated a role for KIPs as assembly molecules for cyclin D<sub>1</sub>-cdk4 and cyclin D<sub>1</sub>-cdk6 complexes. It was shown that KIPs can function to assemble D-type cyclin-cdk complexes *in vitro* and *in vivo*.
46. Cheng M, Olivier P, Diehl JA, *et al*: **The p21(Cip1) and p27(Kip1) CDK 'inhibitors' are essential activators of cyclin D-dependent kinases in murine fibroblasts.** *EMBO J* 1999, **18**:1571–1583.  
This paper provides important confirmation of the assembly function of KIP molecules. Mice lacking both *p21* and *p27* genes were shown to have low levels of cyclin D<sub>1</sub> and to lack cyclin D<sub>1</sub>-cdk4 assembly function. Reconstitution of *p21* and *p27* expression stabilized cyclin D<sub>1</sub> and restored cyclin D-cdk complex formation
47. Laiho M, DeCaprio JA, Ludlow JW, Livingston DM, Massague J: **Growth inhibition by TGF-β1 linked to suppression of retinoblastoma protein phosphorylation.** *Cell* 1990, **62**:175–185.  
This paper was the first to demonstrate that TGF-β inhibits pRb phosphorylation during a limited period in early G<sub>1</sub> phase. It was shown that TGF-β inhibits a pRb kinase and stimulated further investigation of the effects of TGF-β on cyclin-cdk regulation.
48. Howe PH, Draetta G, Leof EB: **Transforming growth factor β1 inhibition of p34cdc2 phosphorylation and histone H1 kinase activity is associated with G1/S-phase growth arrest.** *Mol Cell Biol* 1991, **11**:1185–1194.
49. Schwarz JK, Bassing CH, Kovessi I, *et al*: **Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression.** *Proc Natl Acad Sci USA* 1995, **92**:483–487.
50. Pietenpol JA, Stein RW, Moran E, *et al*: **TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains.** *Cell* 1990, **61**:777–785.
51. Alexandrow MG, Kawabata M, Aakre M, Moses H: **Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta-1.** *Proc Natl Acad Sci USA* 1995, **92**:3239–3243.  
This paper demonstrates that *c-myc* overexpression can abrogate TGF-β-mediated arrest.
52. Jansen-Durr P, Meichle A, Steiner P, *et al*: **Differential modulation of cyclin gene expression by MYC.** *Proc Natl Acad Sci USA* 1993, **90**:3685–3690.
53. Shibuya HJ, Yoneyama M, Ninomiya-Tsuji J, Matsumoto K, Taniguchi T: **IL-2 and EGF receptors stimulate the hematopoietic cell cycle via different signaling pathways: demonstration of a novel role for c-myc.** *Cell* 1992, **70**:57–67.
54. Iavarone A, Massague J: **Repression of the CDK activator Cdc25A and cell-cycle arrest by cytokine TGF-beta in cells lacking the CDK inhibitor p15.** *Nature* 1997, **387**:417–422.  
It was demonstrated that mammary epithelial cells lacking p15 expression can undergo TGF-β-mediated arrest. TGF-β was shown to reduce Cdc25A expression.
55. Warner BJ, Blain SW, Seoane J, Massague J: **Myc downregulation by transforming growth factor beta required for activation of the p15(Ink4b) G(1) arrest pathway.** *Mol Cell Biol* 1999, **19**:5913–5922.  
It was shown that TGF-β resistance resulting from Myc overexpression involves the downregulation of p15 expression by *c-myc*.
56. Geng Y, Weinberg RA: **Transforming growth factor β effects on expression of G1 cyclins and cyclin-dependant protein kinases.** *Proc Natl Acad Sci USA* 1993, **90**:10315–10319.  
It was shown that TGF-β causes inhibition of cyclin E-dependent and cyclin A-dependent kinases, in part through inhibition of cyclin E and cyclin A mRNA levels.
57. Feng X-H, Filvaroff EH, Derynck R: **Transforming growth factor-beta (TGF-beta)-induced down-regulation of cyclin A expression requires a functional TGF-beta receptor complex.** *J Cell Biol Chem* 1995, **270**:24237–24245.
58. Ko TC, Sheng HM, Reisman D, Thompson EA, Beauchamp RD: **Transforming growth factor-β1 inhibits cyclin D1 expression in intestinal epithelial cells.** *Oncogene* 1995, **10**:177–184.
59. Florenes VA, Bhattacharya N, Bani MR, *et al*: **TGF-β mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1 and p27Kip1.** *Oncogene* 1996, **13**:2447–2547.  
That p15 was not essential for TGF-β-induced cell cycle arrest was demonstrated in a melanoma model.
60. Reynisdottir I, Polyak K, Iavarone A, Massague J: **Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β.** *Genes Dev* 1995, **9**:1831–1845.  
This study showed that p15 and p27 cooperate to mediate G<sub>1</sub> arrest. Upregulation of a 15-kDa protein in cdk6 complexes was observed. TGF-β caused release of p27 from cdk4 and cdk6 complexes, and an increase in p27 binding to cyclin E-cdk2. In keratinocytes, p21 levels were increased by TGF-β and p21 binding to cdk2 was increased.
61. Sandhu C, Garbe J, Daksis J, *et al*: **Transforming growth factor β stabilizes p15<sup>INK4B</sup> protein, increases p15<sup>INK4B</sup>-cdk4 complexes and inhibits cyclin D1/cdk4 association in human mammary epithelial cells.** *Mol Cell Biol* 1997, **17**:2458–2467.  
Cooperation between p15 and p27 was demonstrated in HMECs. TGF-β not only induced p15 expression, but also stabilized p15 protein. Cyclin D<sub>1</sub>-cdk4-KIP complexes from a TGF-β-resistant line could not be dissociated by p15 *in vitro*, suggesting that a defect in KIP function may underlie resistance to TGF-β in these cells.
62. Hannon GJ, Beach D: **p15INK4B is a potential effector of TGF-β induced cell cycle arrest.** *Nature* 1994, **371**:257–261.  
This paper describes the cloning of the INK4 family member p15 as a gene that is upregulated by TGF-β.
63. Li JM, Nichols MA, Chandrasekharan S, Xiong Y, Wang XF: **Transforming growth factor beta activates the promoter of cyclin-dependent kinase inhibitor p15INK4B through an Sp1 consensus site.** *J Biol Chem* 1995, **270**:26750–26753.
64. Datto MB, Li Y, Panus JF, *et al*: **Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53 independent mechanism.** *Proc Natl Acad Sci USA* 1995, **92**:5545–5549.  
It is demonstrated that p21 is induced by TGF-β in a p53-independent manner.
65. Malliri A, Yeudall WA, Nikolic M, *et al*: **Sensitivity to transforming growth factor β1-induced growth arrest is common in human squamous cell carcinoma cell lines: c-MYC down-regulation and p21<sup>waf1</sup> induction are important early events.** *Cell Growth Differ* 1996, **7**:1291–1304.
66. Elbendary A, Berchuck A, Davis P, *et al*: **Transforming growth factor β1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells.** *Cell Growth Differ* 1994, **12**:1301–1307.  
It was demonstrated that p21 is upregulated by TGF-β.

67. Hunt KK, Fleming JB, Abramian A, *et al*: **Overexpression of the tumor suppressor gene Smad4/DPC4 induces p21 waf1 expression and growth inhibition in human carcinoma cells.** *Cancer Res* 1998, **58**:5656–5661.
68. Datto MB, Hu PP, Kowalik TF, Yingling J, Wang XF: **The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B.** *Mol Cell Biol* 1997, **17**:2030–2037.
69. Nagahara H, Ezhevsky SA, Vocero-Akbani AM, *et al*: **Transforming growth factor beta targeted inactivation of cyclin E: cyclin-dependent kinase 2 (Cdk2) complexes by inhibition of Cdk2 activating kinase activity.** *Proc Natl Acad Sci USA* 1999, **96**:14961–14966.
70. Galaktionov K, Chen X, Beach D: **Cdc25 cell-cycle phosphatase as a target of c-myc.** *Nature* 1996, **382**:511–517.  
It was shown that c-myc upregulates Cdc25A expression. This effect is not seen in all cell types.
71. Dumont N, Arteaga CL: **Transforming growth factor- $\beta$  and breast cancer: tumor promoting effects of transforming growth factor- $\beta$ .** *Breast Cancer Res* 2000, **2**:125–132.
72. Cairns P, Mao L, Merlo A, *et al*: **Rates of p16 (MTS1) mutations in primary tumors with 9p loss.** *Science* 1994, **265**:415–417.
73. Cairns P, Polascik TJ, Eby Y, *et al*: **Frequency of homozygous deletion at p16/CDKN2 in primary human tumours.** *Nature Genet* 1995, **11**:210–212.
74. Kamb A, Shattuch-Eidens D, Eetes R, *et al*: **Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus.** *Nature Genet* 1994, **8**:23–26.
75. Batova A, Dicciani MB, Yu JC, *et al*: **Frequent and selective methylation of p15 and deletion of both p15 and p16 in T-cell lymphoblastic leukemia.** *Cancer Res* 1997, **57**:832–836.
76. Quesnel B, Guillerm G, Vereecque R, *et al*: **Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression.** *Blood* 1998, **91**:2985–2990.
77. Nakayama K, Ishida N, Shirane M, *et al*: **Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.** *Cell* 1996, **85**:707–720.
78. Kawamata N, Morosetti R, Miller CW, *et al*: **Molecular analysis of the cyclin-dependent kinase inhibitor gene p27<sup>Kip1</sup> in human malignancies.** *Cancer Res* 1995, **55**:2266–2269.
79. Pietenpol JA, Bohlander SK, Sato Y, *et al*: **Assignment of human p27<sup>Kip1</sup> gene to 12p13 and its analysis in leukemias.** *Cancer Res* 1995, **55**:1206–1210.
80. Porter PL, Malone KE, Heagerty PJ, *et al*: **Expression of cell cycle regulators p27kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients.** *Nature Med* 1997, **3**:222–225.
81. Tan P, Cady B, Wanner M, *et al*: **The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas.** *Cancer Res* 1997, **57**:1259–1263.
82. Catzavelos C, Bhattacharya N, Ung YC, *et al*: **Decreased levels of the cell cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer.** *Nature Medicine* 1997, **3**:227–230.
83. Orend G, Hunter T, Ruoslahti E: **Cytoplasmic displacement of cyclin E-cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage-independent cells.** *Oncogene* 1998, **16**:2575–2583.
84. Cipriano SC, Chen YQ: **Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells.** *Oncogene* 1998, **17**:1949–1556.
85. Jiang M, Shao Z-M, Wu J, *et al*: **p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis.** *Int J Cancer* 1997, **74**:529–534.
86. Tsihlias J, Kapusta LR, DeBoer G, *et al*: **Loss of cyclin dependent kinase inhibitor p27<sup>Kip1</sup> is a novel prognostic factor in localized human prostate adenocarcinoma.** *Cancer Res* 1998, **58**:542–548.
87. Lammie GA, Fantl V, Smith R, *et al*: **D11S287, a putative oncogene on chromosome 11q13, is amplified and expressed in squamous cell and mammary carcinomas and linked to BCL-1.** *Oncogene* 1991, **6**:439–444.
88. Buckley MF, Sweeney KJE, Hamilton JA, *et al*: **Expression and amplification of cyclin genes in human breast cancer.** *Oncogene* 1993, **8**:2127–2133.
89. Okamoto A, Jiang W, Kim SJ, *et al*: **Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line.** *Proc Natl Acad Sci USA* 1994, **91**:11576–11580.
90. Nielsen N, Arnerlov C, Emdin S, Landberg G: **Cyclin E overexpression, a negative prognostic factor in breast cancer with strong correlation to estrogen receptor status.** *Br J Cancer* 1996, **74**:874–880.
91. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM: **TGF- $\beta$  inhibition of cdk4 synthesis is linked to cell cycle arrest.** *Cell* 1993, **74**:1009–1020.  
Overexpression of cdk4, but not of cdk2, was shown to abrogate sensitivity to G<sub>1</sub> arrest by TGF- $\beta$ .
92. An H-X, Beckmann MW, Reifenberger G, Bender HG, Niederacher D: **Gene amplification and overexpression of Cdk4 in sporadic breast carcinomas is associated with high tumor cell proliferation.** *Am J Pathol* 1999, **154**:113–118.
93. Perez-Roger I, Kim SH, Griffiths B, Sweing A, Land H: **Cyclins D1 and D2 mediate Myc-induced proliferation via sequestration of p27Kip1 and p21 Cip1.** *EMBO J* 1999, **18**:5310–5320.
94. Bouchard C, Thisted K, Maier A, *et al*: **Direct induction of cyclin D2 by Myc contributes to cell cycle induction and sequestration of p27.** *EMBO J* 1999, **18**:5321–5333.
95. Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B: **Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc.** *EMBO J* 1996, **15**:6595–6604.
96. Filmus J, Zhao J, Buick RN: **Overexpression of H-ras oncogene induces resistance to the growth-inhibitory action of transforming growth factor beta-1 (TGF-beta 1) and alters the number and type of TGF-beta 1 receptors in rat intestinal epithelial cell clones.** *Oncogene* 1992, **7**:521–526.
97. Kretzschmar M, Doody J, Timokhina I, Massague J: **A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras.** *Genes Dev* 1999, **13**:804–816.
98. Cheng M, Sexl V, Sherr CJ, Roussel MF: **Assembly of cyclin D-dependent kinase and titration of p27Kip1 regulated by mitogen-activated protein kinase kinase (MEK1).** *Proc Natl Acad Sci USA* 1998, **95**:1091–1096.
99. Diehl JA, Cheng M, Roussel MF, Sherr CJ: **Glycogen synthase kinase-3 beta regulates cyclin D1 proteolysis and subcellular localization.** *Genes Dev* 1998, **12**:3499–3511.
100. Ram TG, Ethier SP: **Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/hergulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.** *Cell Growth Differ* 1996, **7**:551–561.



101. Brennan P, Babbage JW, Burgering BMT, *et al*: **Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F**. *Immunity* 1997, **7**:679–689.
102. Gerwin BI, Spillare E, Forrester K, *et al*: **Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce responsiveness to a negative growth factor, transforming growth factor  $\beta$ 1**. *Proc Natl Acad Sci USA* 1992, **89**:2759–2763.
103. Reiss M, Vellucci VF, Zhou ZL: **Mutant p53 tumor suppressor gene causes resistance to transforming growth factor beta 1 in murine keratinocytes**. *Cancer Res* 1993, **53**:899–904.
104. Wyllie FS, Dawson T, Bond JA, *et al*: **Correlated abnormalities of transforming growth factor- $\beta$ 1 response and p53 expression in thyroid epithelial cell transformation**. *Mol Cell Endocrinol* 1991, **76**:13–21.
105. Sun P, Dong P, Dai K, Hannon GJ, Beach D: **p53-independent role of MDM2 in TGF-beta 1 resistance**. *Science* 1998, **282**:2270–2272.
106. Bueso-Ramos CE, Manshour T, Haidar MA, *et al*: **Abnormal expression of MDM-2 in breast carcinomas**. *Breast Cancer Res Treat* 1996, **37**:179–188.
107. Gunther T, Schneider-Stock R, Rys J, Niezabitowski A, Roessner A: **p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinicopathological factors**. *J Cancer Res Clin Oncol* 1997, **123**:388–394.

**Authors' affiliations:** Jeffrey Donovan (Department of Medical Biophysics, University of Toronto, and Division of Cancer Research, Toronto Sunnybrook Regional Cancer Centre and Sunnybrook and Women's College Health Sciences Centre, Ontario, Toronto, Canada) and Joyce Slingerland (Departments of Medicine and Medical Biophysics, University of Toronto, and Division of Cancer Research, Toronto Sunnybrook Regional Cancer Centre and Sunnybrook and Women's College Health Sciences Centre, Ontario, Toronto, Canada)

**Correspondence:** Joyce Slingerland, Division of Cancer Research, Sunnybrook and Women's College Health Sciences Centre, 2075 Bayview Ave, Toronto, Ontario, Canada M3N 3M5.  
Tel: +416 480 6100, ext 3494; fax: +416 480 5703;  
e-mail: joyce.slingerland@utoronto.ca